Valore clinico dei nuovi dati biologici


Published: June 8, 2009
Abstract Views: 797
PDF: 9354
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

La diagnosi di malattia mieloproliferativa cronica (MMPC) Philadelphia-negativa si basa sui criteri stabiliti dalla classificazione WHO.1 Tale classificazione ha introdotto l’impiego della biopsia osteomidollare come procedura principale per la diagnosi di trombocitemia essenziale (TE) e mielofibrosi idiopatica (CIMF) e come procedura secondaria per la diagnosi di policitemia vera (PV).

Supporting Agencies


Boveri, E., Castello, A., Passamonti, B. F., Rumi, E., Elena, C., Lazzarino, M., & Cazzola, M. (2009). Valore clinico dei nuovi dati biologici. Hematology Meeting Reports (formerly Haematologica Reports), 2(6). https://doi.org/10.4081/hmr.v2i6.387

Downloads

Citations